Mr. Miguel Martin reports

AURORA CANNABIS INC. ANNOUNCES CLOSING OF ITS C$38.8 MILLION BOUGHT DEAL FINANCING, INCLUDING THE FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

Aurora Cannabis Inc. today closed its previously announced bought deal offering of 53,187,500 common shares of the company at a price of 73 cents per offered security, for aggregate gross proceeds to Aurora of approximately $38,826,875. The gross proceeds include the full exercise of the overallotment option by Canaccord Genuity to purchase 6,937,500 additional common shares of the company on the same terms as the offering.

"It is our intention to use the majority of the net proceeds from the offering to repay the remaining balance of our convertible notes at or prior to maturity, representing principal outstanding of approximately $25-million (U.S.). Pro forma the offering but prior to any repayment of convertible notes, Aurora has a highly flexible capital structure, with approximately $227-million of total cash available to support strategic growth initiatives and value accretive M&A opportunities. As a result of the offering, we do not believe that we will need to pursue an at-the-market offering program for the medium term, as we expect to deliver on our stated objective of being free cash flow positive in calendar 2024," stated Aurora's chief executive officer, Miguel Martin.

A prospectus supplement to the company's short form base shelf prospectus dated April 27, 2023, has been filed with the securities commissions or securities regulatory authorities in each of the provinces of Canada, except Quebec. Copies of the prospectus supplement and the base shelf prospectus may be obtained on SEDAR+ and from Canaccord Genuity Corp., 40 Temperance St., suite 2100, Toronto, Ont., M5H 0B4. The prospectus supplement and the base shelf prospectus contain important detailed information about the company and the offering. Prospective investors should read the prospectus supplement, the base shelf prospectus and the other documents the company has filed on SEDAR+ before making an investment decision.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched.

We seek Safe Harbor.